Abstract
Tinnitus, a phantom sensation experienced by people around the world, currently is endured without a known cure. Some find the condition tolerable, while others are tortured on a daily basis from the incessant phantom noises. For those who seek treatment, oftentimes, they have a comorbid condition (e.g., depression, anxiety, insomnia), which is treated pharmaceutically. These products aim to reduce the comorbities associated with tinnitus thereby minimizing the overall burden present. Because of the phantom nature of tinnitus, it is often compared to neurologic pain. Since pain can be managed with pharmaceutical options, it is reasonable to assume that similar agents might work to alleviate tinnitus. The effects of antidepressants, benzodiazepines, anticonvulsants, and glutamate antagonists are reviewed in this paper. Table 1 summarizes the pharmaceutical products discussed. Due to the variety of comorbid factors and potential causes of tinnitus, there may not be one pharmaceutical treatment that will combat every type of tinnitus. Nevertheless, a product that finally addresses the true cause of tinnitus, and not just its comorbidities, will benefit millions of people worldwide.
Keywords: Angiotensin-converting enzyme (ACE), anticonvulsants, antidepressants, benzodiazepines, COX2, cyclooxygenase (COX)1, glutamate antagonists, tinnitus, vitamins.
Current Neuropharmacology
Title:The Management and Outcomes of Pharmacological Treatments for Tinnitus
Volume: 13 Issue: 5
Author(s): Devon Beebe Palumbo, Kathleen Joos, Dirk De Ridder and Sven Vanneste
Affiliation:
Keywords: Angiotensin-converting enzyme (ACE), anticonvulsants, antidepressants, benzodiazepines, COX2, cyclooxygenase (COX)1, glutamate antagonists, tinnitus, vitamins.
Abstract: Tinnitus, a phantom sensation experienced by people around the world, currently is endured without a known cure. Some find the condition tolerable, while others are tortured on a daily basis from the incessant phantom noises. For those who seek treatment, oftentimes, they have a comorbid condition (e.g., depression, anxiety, insomnia), which is treated pharmaceutically. These products aim to reduce the comorbities associated with tinnitus thereby minimizing the overall burden present. Because of the phantom nature of tinnitus, it is often compared to neurologic pain. Since pain can be managed with pharmaceutical options, it is reasonable to assume that similar agents might work to alleviate tinnitus. The effects of antidepressants, benzodiazepines, anticonvulsants, and glutamate antagonists are reviewed in this paper. Table 1 summarizes the pharmaceutical products discussed. Due to the variety of comorbid factors and potential causes of tinnitus, there may not be one pharmaceutical treatment that will combat every type of tinnitus. Nevertheless, a product that finally addresses the true cause of tinnitus, and not just its comorbidities, will benefit millions of people worldwide.
Export Options
About this article
Cite this article as:
Beebe Palumbo Devon, Joos Kathleen, De Ridder Dirk and Vanneste Sven, The Management and Outcomes of Pharmacological Treatments for Tinnitus, Current Neuropharmacology 2015; 13 (5) . https://dx.doi.org/10.2174/1570159X13666150415002743
DOI https://dx.doi.org/10.2174/1570159X13666150415002743 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Bioorganic Compounds Produced by the Fungus Monascus and their Use in Health Sciences and Medicine
Mini-Reviews in Organic Chemistry Novel Systemic Drugs for Cutaneous T-Cell Lymphoma
Recent Patents on Anti-Cancer Drug Discovery Natural Products Based Ayurvedic Formulations: Chemical Cons tituents and Treatment in Neurodegenerative Disordersǂ
Mini-Reviews in Organic Chemistry Genomics of Addiction
Current Psychiatry Reviews Neuroprotection by Alpha 2-Adrenergic Agonists in Cerebral Ischemia
Current Neuropharmacology Regulation of Angiogenesis by the Kallikrein-Kinin System
Current Pharmaceutical Design Perspectives on Brain-Targeting Drug Delivery Systems
Current Pharmaceutical Biotechnology Simultaneous Determination of Cytochrome P450 Oxidation Capacity in Humans: A Review on the Phenotyping Cocktail Approach
Current Pharmaceutical Biotechnology Obesity-Induced Cerebral Hypoperfusion Derived from Endothelial Dysfunction: One of the Risk Factors for Alzheimer's Disease
Current Alzheimer Research Global Cerebral Ischemia: Synaptic and Cognitive Dysfunction
Current Drug Targets Targeting Trail Towards the Clinic
Current Drug Targets TakoTsubo Cardiomyopathy A Short Review
Current Cardiology Reviews Endothelin-Converting Enzyme Inhibitors
Current Enzyme Inhibition Continuous Infusion of Antibiotics in Critically Ill Patients
Current Clinical Pharmacology Naturally Occurring and Related Synthetic Cannabinoids and their Potential Therapeutic Applications
Recent Patents on CNS Drug Discovery (Discontinued) Use of Corticosteroids in Critically Ill Septic Patients: A Review of Mechanisms of Adrenal Insufficiency in Sepsis and Treatment
Current Drug Targets Synthesis and DPPH Radical Scavenging Activity of 5-Arylidene-N,Ndimethylbarbiturates
Medicinal Chemistry An Update on Peptide Drugs for Voltage-Gated Calcium Channels
Recent Patents on CNS Drug Discovery (Discontinued) Inflammatory Mediators and the Failing Heart: A Translational Approach
Current Molecular Medicine Critical Questions for Preclinical Trials on Safety and Efficacy of Vascular Endothelial Growth Factor-Based Therapeutic Angiogenesis for Ischemic Stroke
CNS & Neurological Disorders - Drug Targets